DENTSPLY SIRONA Stock Gets New $14 Price Target

Analysts at Robert W. Baird raise price objective on the medical instruments supplier's shares.

Feb. 27, 2026 at 1:25pm

Got story updates? Submit your updates here. ›

Analysts at Robert W. Baird have increased their price target on shares of DENTSPLY SIRONA (NASDAQ:XRAY) from $12.00 to $14.00, while maintaining a "neutral" rating on the stock. The new price target represents a potential upside of 10.15% from the stock's previous close.

Why it matters

DENTSPLY SIRONA is a leading global manufacturer of professional dental products and technologies. The company's stock performance and analyst coverage are closely watched by investors in the medical instruments and dental care sectors.

The details

In a research note issued on Friday, the analysts at Robert W. Baird cited the company's recent financial performance and market positioning as reasons for the price target increase. DENTSPLY SIRONA reported mixed quarterly results in late February, with earnings per share missing analyst estimates but revenue coming in ahead of expectations.

  • The new $14.00 price target was issued on February 27, 2026.

The players

DENTSPLY SIRONA

A leading global manufacturer of professional dental products and technologies, headquartered in Charlotte, North Carolina.

Robert W. Baird

A financial services firm that provides investment banking, asset management, wealth management, and private equity services.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The price target increase from Robert W. Baird suggests analysts see potential upside in DENTSPLY SIRONA's stock despite the company's recent mixed financial performance. Investors will be watching to see if the stock can regain momentum and reach the new $14 price target.